CD44 and neoplasm: As shown in Figure 2A and B, patients with HPVDNA+ tumors and an absent/weak CD44 intensity had a significantly better DFS (96% vs. 86%) and OS (95% vs. 80%) compared with patients with HPVDNA+ and medium/strong CD44 intensity tumor expression (P = 0.034 and P = 0.060, respectively).